– Numan is a digital platform for men’s health.
– Company raised $40m in Series B funding.
– The round was led by White Star Capital, with participation from existing investors Novator, Vostok New Global, Anthemis Exponential and Colle Capital, and new investor Hanwha Dream Fund.
– The new investment will be used to continue to expand operations and its business reach, as well as the therapeutic areas it covers.

– Vibrato Medical has closed a $4M Series A funding round led by the Horowitz Group, a multi-asset class family investment office based in Newport Beach, CA.
– The company has also received a $1.5M NIH grant.
– This funding will support the clinical trial of the company’s novel, noninvasive, wearable device designed to treat patients with critical limb ischemia (CLI), an advanced stage of peripheral arterial disease (PAD).
– The therapeutic ultrasound has shown to promote vasodilation and long-term blood vessel growth in weeks and is appropriate for daily treatments.

– TurningPoint Healthcare Solutions, a Lake Mary, Fla.-based leader in advanced clinical and technology-enabled complex care management, received a growth funding of undisclosed amount.
– The round was led by Summit Partners, with participation from Oak HC/FT and existing investor Sopris Capital.
– The new investment will enable the company to expand into areas of healthcare, enhance its innovative technology and product offering, and expand its geographic presence.

– Nectero Medical Inc. announced the closing of its $19.5m Series C financing round.
– Proceeds will support the company‘s in vivo and clinical trials to develop a potentially disruptive treatment platform that stabilizes small– to mid–sized aortic aneurysms by significantly reducing their growth rate.

– Seattle-based startup RareCyte announced $24m in new funding.
– The funding will fuel the commercialization and development of its new Orion cell imaging and analysis platform, launched last year.
– The company markets kits for preparing samples from blood or tissues and instruments to optically measure cells.
– Their products aim for automation and high-volume of sampling.

– Owlstone Medical is a Cambridge UK-based global leader in Breath Biopsy® for applications in early disease detection and precision medicine.
– Company raised $58m in funding.
– The round was led by Horizons Ventures, which now takes a seat on Owlstone Medical’s Board, and is joined by other existing and high-profile new investors from Asia, the Middle East and the United States.
– The new investment will be used to accelerate the company’s commercialization of its Breath Biopsy tests.

– contextflow from Vienna develops artificial intelligence for medical image analysis.
– A second closing included an additional €2M from new co-investor Peak Pride Management GmbH, HPH (Hans Peter Haselsteiner) Start-up Unit and current investor APEX Ventures with its “APEX Best in Class” fund. A first closing was led by B&C Innovation Investments GmbH (BCII) and included participation from new co-investor TTIP Beteiligungs GmbH and current investors APEX Ventures, Crista Galli Ventures, IST cube, Nina Capital and Novacapital.
– The new investment will be used to accelerate market entry in Europe and the US, including obtaining FDA clearance for contextflow SEARCH Lung CT, as well as extending its offerings to include new products and features covering a wider range of organs and modalities.

– Locate Bio is pleased to announce that it has raised an oversubscribed £10 million of equity investment in a funding round co-led by existing shareholder Mercia Asset Management and new investor BGF.
– The funding will be used to further advance Locate Bio’s proprietary pipeline of regenerative orthobiologics products towards patients, with key clinical and regulatory milestones expected to catalyse growth over the next two years.
– The investment brings the total funds raised by Locate Bio to over £18 million. The company’s lead product in development is called LDGraft, and is a low dose, controlled release rhBMP-2 for the treatment of degenerative disc disease.

– Minnesota based Laplace Interventional, a medical device company developing a transcatheter tricuspid valve technology, announced that it has closed on its Series A financing led by a non-disclosed major strategic investor along with a significant investment from ShangBay Capital, an early stage medical device investor as well as other investors.
– The $7.9M Series A financing round will fund Laplace Interventional towards achieving its preclinical milestones.
– The company also announced the addition of two Directors to its Board including William Dai, Founding Managing Partner at ShangBay Capital.
– Laplace Interventional’s device aims to offer an increase in life expectancy and an improvement to the quality of life to several patients worldwide diagnosed with Tricuspid Regurgitation (TR).

– Onkos Surgical has raised $15m in Series C funding from its existing investor syndicate.
– The new funding will drive revenue growth by accelerating the company’s research and development pipeline, expanding its commercial footprint, and evolving manufacturing capabilities.
– These investments support the company’s focus on delivering surgeon-driven and patient-inspired approaches to address three main clinical challenges of complex orthopaedic procedures – implant loosening, soft tissue failures, and infection.

– Tissium is a medtech company developing biomorphic programmable polymers for tissue reconstruction.
– Company raised €50M in Series C financing.
– The round was led by Cathay Health, affiliated to global investment firm Cathay Capital, with participation from existing shareholders Sofinnova Partners, and others.
– The company intends to use the funds to continue to execute on its development plan, up to the commercialization of its nerve repair, hernia repair and cardiovascular sealant products.

– Trice Medical, a Malvern, PA-based imaging technology company, raised a Series D funding.
– The amount of the deal was not disclosed.
– The funding was led by Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing.
– In conjunction with leading the funding, Bioventus will receive exclusive sales and distribution rights to Trice’s products outside of the US.

– Abtrace is a London UK-based healthtech startup.
– The company raised £2.1M in seed funding.
– The round was led by Faber with participation from Ganexa Capital.
– The new investment will be used to roll out the technology to new GP practices across the UK and expand their engineering and data science teams.

– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.

– Checkpoint Surgical, Inc. completed a $16m capital raise led by River Cities Capital, a Cincinnati-based healthcare-focused growth equity firm.
– Existing backers also participated in the round, including Cleveland-based venture funds Mutual Capital Partners and JumpStart NEXT Fund, First Analysis, a growth equity firm based in Chicago, and several other investors.
– The growth capital will be used to support Checkpoint’s sales force expansion and multiple new product launches, including the recently acquired NeuroShield nerve wrap, as well as fueling continued research and development efforts.
– With a specialized, dedicated sales force of 30 and growing, and a substantial multi-disciplinary R&D team, Checkpoint Surgical is well equipped to scale the business rapidly.

– SCAN Group, whose holdings include SCAN Health Plan, one of the nation’s largest not-for-profit Medicare Advantage plans, has made a strategic investment in MedArrive.
– MedArrive is a healthcare logistics and services platform that enables payers and providers to leverage a network of EMTs, paramedics and other types of skilled healthcare workers to extend care services into the home, improving patient outcomes while empowering an underutilized segment of the healthcare workforce.

– Zilia is a Quebec, Canada-based ocular health startup.
– Company raised $4m in seed funding.
– The round was led by Anges Québec, with participation from the Government of Quebec through its new program, Impulsion PME, administered by Investissement Québec as a government agent, and other backers.
– The new investment will be used to complete the regulatory approval process for the clinical launch of Zilia Ocular, its first product.

– Israeli stroke therapy technology startup, BrainQ, today announced a $40m funding round led by Hanaco Ventures, along with Dexcel Pharma, and Peregrine Ventures.
– The funding will be used to support a multicenter pivotal trial for its groundbreaking technology for ischemic stroke survivors in selected US hospitals.
– This year, BrainQ received FDA Breakthrough Device Designation allowing the company to work closely with the FDA to expedite development plans and premarket clearance, with access to the new Medicare Coverage of Innovative Technology pathway.

– Fluid Biotech Inc. from Calgary, AB, Canada closed a $4.7m seed funding round.
– The round was led by Metis Innovative of Miami and ShangBay Capital of Palo Alto, California, with participation from new investors UCeed Health Fund and UCeed Child Health and Wellness Fund from the University of Calgary, Thin Air Labs, Wharton Alumni Angels, Amino Capital, Bluesky Equities, ThresholdImpact and Alabaster Capital.
– The company intends to use the funds to engage contract manufacturers to initiate production, complete regulatory milestones, and plan for first-in-human implantation.

– Berry Oncology Corporation, a member company of China’s leading early cancer screening firm Berry Genomics, closed a US$99.15m Series B1 financing round.
– This round was led by China Merchants Capital Management Co., Ltd. Existing investors Qiming Venture Partners and Legend Capital, along with new investors including Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management Co., Ltd., Xiamen C&D Emerging Industry Equity Investment Co., Ltd. and other investors also participated.
– The new proceeds will enable the company to meet the demand for early cancer screening and diagnosis and boost its expansion in the market.

– Encellin closed a $5.9M Seed financing round.
– The round was co-led by Khosla Ventures and SV Latam Capital, with participation from Sandhill Angels and Y Combinator.
– The new funding will be used to advance development of its technology platform and programs in hypoglycemia and hypocalcemia.
– Encellin will also expand into areas with readily available renewable cell sources and engineered cells, to encapsulate any cellular cargo in products from its proprietary platform.
– Encellin builds implantable “cell pouches” to treat chronic diseases.
– The company’s technology combines ad novel cell encapsulation technology with functional cell therapies to treat chronic diseases, starting with endocrine disorders.

– Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announces it has raised $12M in a Series B Plus funding round.
– Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round.
– The financing will support Eyevensys’ accelerated development of its EYS809 program for the treatment of wet age-related macular degeneration (AMD), a chronic eye disorder that causes blurred vision or a blind spot in the eye. The condition accounts for approximately 90 percent of all AMD-related blindness. Additionally, the company will advance its EYS611 program targeting geographic atrophy (GA) and retinitis pigmentosa.

– Scivita Medical Technology Co., Ltd. from Hong Kong is a maker of endoscopy products.
– The company received nearly RMB0.4 Billion in Series B financing.
– Backers included new investors such as Hudson Bay Capital Management and Prime Capital, as well as existing shareholders such as GL Ventures, Lilly Asia Ventures and Matrix Partners China.
– The new investment will be used for research and development, capacity expansion, and domestic and international commercialization of innovative products in endoscopy and related fields.

– Onera closed the Series B funding round, which brought the total funding raised to date above the €24M mark.
– Innovation Industries led the round in collaboration with Invest-NL and with existing investors Jazz Pharmaceuticals, imec.xpand, BOM and 15th Rock.
– The company intends to use the funds to execute clinical studies and further commercialize its sleep diagnostics and monitoring products in Europe and the United States.
– Onera recently relocated its headquarters to the Brainport region in Eindhoven, the Netherlands, while maintaining commercial operations in the United States.

– Connie Health, a Medicare concierge service, raised $13m in Series A funding.
– The round was led by Khosla Ventures and Pitango Healthtech.
– It brings the company to a total of $16m in funding.
– With 55 million Medicare consumers benefiting from major innovation in Medicare Advantage and value-based care, Samir Kaul, founding general partner at Khosla Ventures, saw a large market that was being disrupted by Connie Health.
– The company’s three co-founders, Oded Eran, CEO, David Luna, chief revenue officer, and Michael Scopa, chief growth officer, saw this problem firsthand as executives at primary care company Iora Health, which is being acquired by OneMedical for $2.1 billion.

– Exo, a handheld ultrasound device and point-of-care workflow platform, raised $220m funding.
– The round was led by RA Capital Management and joined by BlackRock, Sands Capital, Avidity Partners, Pura Vida Investments and prior investors.
– The company plans to use the funding to commercialize its device and to build out its informatics platform.

– BioIntelliSense, Inc. from Denver provides continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM).
– Series B $45m round was led by Chimera (UAE) and joined by 7wire Technology Partners, Mary Tolan of Chicago Pacific Founders, James Murren formerly of MGM Resorts International, as well as Pendrell Corporation, Royal Philips, and Fresenius Medical Care North America.
– The new investment will be used to accelerate the company’s growth and global expansion.

– Strata Oncology, Inc. from Ann Arbor develops a comprehensive genomic profiling platform to deliver a portfolio of treatment selection tests for solid tumors.
– Series C $90m financing was led by Wellington Management and joined by other new investors.
– The new investment will be used to accelerate the company’s pipeline of novel RNA-based treatment selection tests for solid tumors.

– Signifier Medical announced that it has successfully raised $35m in its Series D capital raise.
– This financing will underpin the commercialization of Signifier’s FDA-approved De Novo device and therapy, eXciteOSA®, to treat millions of patients around the world suffering from primary snoring and mild obstructive sleep apnea (OSA).
– The lead investors in the financing were Segulah Medical Acceleration, Angelus Venture Fund I L.P., Alan Howard (co-founder of Brevan Howard Asset Management) and Pioneer Healthcare Partners LP.

– neuro42, the medical technology company leading the next evolution of MRI and robotics, announced the close of a $6.5M Series A financing round.
– Zepp Health led the financing round and is joined by ShangBay Capital and prominent angel investors, Krishna R. Bhupal and Philip Dolan.
– The financing will enable neuro42 to advance the development of the first-of-its-kind MRI and robot, and allow physicians to diagnose brain injury in acute settings and treat neurological diseases intraoperatively under live imaging.
– To date, the Company has raised $7.8M of which $1.3M was in an oversubscribed seed round that closed earlier this year.

– Hochuen Medical from Shenzhen is developing and producing microfluidic and IVD devices for more than 200 companies.
– The company raised RMB 40M in Series A funding.
– The round was led by Qiming Venture Partners.
– The new investment will be used to accelerate the company’s contract development and manufacturing organization, expand in both international and domestic markets, develop new manufacturing processes and technologies, and further expand production capacity.

– Eyenuk, a Los Angeles CA-based artificial intelligence (AI) medical technology and services company, raised $6.2M in funding.
– The round was led by AXA IM, through AXA IM Alts.
– The company intends to use the funds to accelerate commercialization of the EyeArt® AI System.

– Paradromics, an Austin, Texas-based developer of high data rate Brain Computer Interfaces (BCI), raised $20M in seed funding.
– The round was led by Prime Movers Lab with participation from Westcott Investment Group, Dolby Family Ventures, Synergy Ventures, Pureland Global Venture, IT-Farm, and Alpha Edison.
– As part of the investment from Prime Movers Lab, Partner Dr. Amy Kruse will be joining the Paradromics Board of Directors.

– Leo Cancer Care is a Horley, UK- and Middleton, Wisconsin-based radiation therapy startup.
– The company raised $25.3m in Series B funding.
– The round was led by Pureland Global Venture, Yu Galaxy, WARF, Alumni Ventures, Junson Capital and Serra Ventures as well as industry leaders CHC, Cosylab, Toret Devices and Radiation Business Solutions.
– The new investment will be used to expand their teams in the US, Europe and Singapore and continue the development of its upright radiotherapy solutions.

– Neuspera Medical Inc. closed a $65m series C equity financing.
– The round was co-led by Vertex Ventures HC and Treo Ventures with participation from returning Series A and Series B investors Action Potential Venture Capital and Windham Venture Partners.
– The new funding will be used to conduct the SANS-UUI pivotal clinical study of its miniaturized implantable neuromodulation technology platform for use in subjects with Urinary Urgency Incontinence, a symptom of overactive bladder (OAB).

– Omniscient Neurotechnology (“o8t™”), a pioneering brain mapping technology company, announced the completion of an AUD 40 million Series B financing round.
– The funding was led by family offices and high-net worth individuals, including Hancock Prospecting’s Executive Chairman Mrs. Gina Rinehart, and prominent fund manager Will Vicars.
– Using innovations in medical imaging and machine learning, Omniscient builds applications capable of modelling and analyzing connectomes or brain networks which are formed by the electrical connections within an individual’s brain.
– This technology transforms complex brain data into clear insight for doctors, psychologists, neuroscientists and brain technology innovators to better treat neurological disorders and mental illnesses.

– Dopavision, a Berlin, Germany-based company focused on development of digital therapeutics, raised €12M in Series A funding.
– The round was led by Seventure Partners with participation from Novartis Pharmaceuticals, Boehringer Ingelheim Venture Fund and Ababax Health.
– The new investment will be used for the clinical development of MyopiaX, its lead product in childhood myopia, activities to provide innovative digital treatments for children leveraging games, educational or cognitive training applications, and potentially broaden its pipeline to new indications.

– Imperative Care, Inc. announced that it has closed a $260m Series D financing led by D1 Capital Partners.
– New investors HealthCor Investments LLC and Innovatus Capital Partners also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures participated in the financing.
– James Rogers from D1 will join Imperative Care’s Board of Directors.
– Proceeds from the financing will be used to support ongoing commercialization and development of a wide range of Imperative Care’s technologies in the broad continuum of stroke care, as well as to create a strategic network of wholly owned development subsidiaries in a number of areas of synergy.

– Swift Medical is a digital wound care company based in Toronto.
– The company raised $35M in Series B funding.
– The round was led by Virgo Investment Group LLC with participation from DCVC, BDC Capital, Women in Technology Venture Fund, Claritas Capital, Chrysalis Ventures, Pender Ventures and Export Development Canada.
– The investment will be used to expand the company’s market position and scale their digital wound management platform across North America.

– Ribon Therapeutics announced the closing of a $65m financing.
– The financing was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation, Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group.
– Ribon will use the proceeds to support the clinical development of its novel precision medicine candidates.

– Suono Bio, Inc. is a biotech company based in Foxborough, Massachusetts.
– The company raised $8.5m in Series A funding.
– The round was led by Axil Capital and Mizuho Securities Principal Investment with participation from Taiwania Capital and other investors.
– The new funding will be used to advance its lead programs in inflammatory bowel disease as well as expansion of its pipeline.

– Aidoc, a Tel Aviv, Israel-based AI for medical imaging company, raised $66M in Series C funding.
– The round was led by General Catalyst.
– The company intends to use the fund to expand operations and its business reach.

– Suono Bio, Inc. has raised an $8.5m Series A financing led by Axil Capital and Mizuho Securities Principal Investment, with participation by Taiwania Capital and other investors.
– Suono Bio will utilize the funds to advance its lead programs in inflammatory bowel disease as well as expansion of its pipeline.
– The company leverages technology developed in the laboratory of Institute Professor Robert Langer at the Massachusetts Institute of Technology (MIT) to facilitate rapid, local administration of therapeutics to treat serious diseases.
– The company was founded by Professor Langer, Professor Giovanni Traverso, from the Department of Mechanical Engineering at MIT and a gastroenterologist and biomedical engineer at Brigham and Women’s Hospital, Harvard Medical School, and Dr. Carl Schoellhammer.

– Single Pass, Inc. from Lake Forest CA provides a bipolar electrocautery device that can cauterize deep tissue through a guide needle.
– The company raised an undisclosed amount in seed funding.
– The round was led by Tech Coast Angels of San Diego with participation from Kyto Technology and Life Science, Inc.
– The new investment will be used to expand operations and accelerate growth.

– Fourier Intelligence Co., Ltd. from Shangai, China, completed a C+ financing round of undisclosed amount.
– The round was led by Prosperity7 Ventures, the diversified growth fund of Aramco Venture.
– The company intends to use the funds to invest more into core technology development, talent acquisition and global market expansion.

– Incisive Genetics Inc. closed its $2.5 million seed financing.
– The financing syndicate was led by investors Noel Hall and Sandra MacPherson of the MacHall group and Haig Farris, OC.
– This funding will enable Incisive Genetics to develop its manufacturing process and capabilities, advance key studies to enhance its gene editing delivery platform technology, and further add to its intellectual property portfolio.

– Osso VR, a validated virtual reality (VR) surgical training and assessment platform, has secured $27M in Series B funding.
– GSR Ventures led the funding round with participation from Signalfire, Kaiser Permanente Ventures, OCA Ventures, Scrum Ventures, Leslie Ventures and Anorak Ventures.
– Osso VR’s surgical training technology provides on-demand, educational experiences that are effective, repeatable and measurable to help surgeons reach proficiency with emerging surgical techniques and technologies.

– Tioga Medical, Inc. announced the initial closing of its committed $30M Series B financing.
– Led by The Capital Partnership (TCP), with participation from Cormorant Asset Management, AMED Ventures and Shifamed angel investors.
– The financing will be used to advance product development, support pre-clinical testing, and initiate clinical experience for the company’s novel transcatheter valve replacement technology.

– RapidPulse from Miami FL raised $15M in Series A funding.
– The round was led by Santé Ventures with participation from Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon.
– The company plans to use the funds to advance its system through expanded clinical evaluation and build out its platform of proprietary catheters.

– EchoNous, the leader in portable AI-guided ultrasound tools and software, announced it has raised $60m in funding from Kennedy Lewis Investment Management, a leading opportunistic credit manager with a strong track record of supporting innovative life sciences companies. The investment from Kennedy Lewis combines senior secured debt and equity and builds on the support of KKR, which has been EchoNous’ principal investor since 2015.
– Proceeds from the financing will help fuel the commercial launch of Kosmos, EchoNous’ flagship device. Kosmos is the first AI-guided point-of-care ultrasound (POCUS) system to provide diagnostic-quality imaging on par with larger, less portable, and more expensive imaging machines.

– Babson Diagnostics announced a $31m Series B financing round.
– The round was led by Emerald Development Managers with participation from Siemens Healthineers, Prism Ventures, and Lago Consulting Group.
– Babson Diagnostics is a transformative medical technology company improving customer access to diagnostic blood testing.
– Babson intends to use the Series B funding to expand its laboratory and ecosystem infrastructure, finalize its blood testing solution development, and grow its sales and marketing teams.
– Neil Cohen, founder and chairman of Emerald Development Managers, will join the company’s board of directors.

– CMR Surgical is a Cambridge UK-based surgical robotic company.
– Series D $600M round was led by SoftBank Vision Fund 2 with participation from Ally Bridge Group, new investors RPMI Railpen, Tencent and Chimera, and existing investors LGT and its affiliate impact investing platform Lightrock, Watrium, Cambridge Innovation Capital, PFM Health Sciences and GE Healthcare.
– The investment will be used for the global commercialization of Versius and further develop the company’s digital ecosystem.

– SHINE Medical Technologies LLC announced that it has closed a $150-million Series C-5 financing.
– Koch Disruptive Technologies led the round, which also included participation by Fidelity Management & Research Company, Baillie Gifford and other new and current investors.
– The financing will support SHINE’s commercialization of its diagnostic and therapeutic medical isotope technologies and position the company for future growth as it works toward developing new fusion-based technology applications.
– An existing SHINE facility produces the therapeutic medical isotope lutetitum-177 (Lu-177).
– Radiotherapeutics are one of the fastest growing areas of oncology and has significant potential for the treatment of several cancers because of their ability to directly irradiate cancer including at the late stages.

– Palliare is a Galway, Ireland-based safe operating room company.
– The company closed an $8m Series A funding round led by Seroba Life Sciences with participation from SCM AD Ventures, Western Development Commission, and several private investors.
– The company intends to use the funds to support US commercial launch activities related to its EVA15 insufflator and smoke evacuation system, as well as new Research & Development activities.

– Cardiac Success Ltd. from Yokneam closed US $5.2M Series A funding.
– The round was led by 415 Capital, a specialist medical technology venture capital firm who was joined by an unnamed strategic investor and global leader in structural heart interventions.
– The company intends to use the funds for pre-clinical testing and the completion of a First-in-Human trial its “V-sling” heart failure therapy.

– Quanta Dialysis Technologies announced that it has raised $245m in an oversubscribed and upsized Series D round.
– The round was led by Glenview Capital and co-led by Novo Holdings, with support from a broad group of other top-tier investors.
– Quanta’s award-winning portable hemodialysis system SC+ is the only next-generation system that delivers the performance and dose equivalence of larger, traditional dialysis systems—with on-demand dialysate production and high dialysate flow rates—while also offering the portability, digital connectivity and ease-of-use of a next-generation dialysis device.
– The funding will allow Quanta to accelerate its emergence as a significant force in this market.

– Leukocare AG, a Martinsried/Munich, Germany and Milford, MA, USA-based biotechnology company specialized in the field of biopharmaceutical formulation development, closed a USD 17.5m (€14.6m) financing.
– The round was led by Petrichor Healthcare Capital Management with participation from existing shareholders.
– Proceeds will be used to accelerate Leukocare’s US expansion activities, bolster the company’s expertise in the fields of viral vector and vaccine formulation, as well as the emerging field of mRNA formulation, and to expand its suite of bioinformatics capabilities.

– Fractyl Health closed a $100m Series F financing.
– The financing was led by Maverick Capital, M28 Capital, and Population Health Partners, with participation by other new and existing investors.
– Marc Elia, founder of M28 Capital, and Clive Meanwell, M.D., Ph.D., executive chairman and founder of Population Health Partners, have joined Fractyl’s Board of Directors.
– Proceeds from the financing will support initiation of multiple late-stage clinical studies to assess the potential for Revita DMR to treat and halt the progression of metabolic disease.

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

– Owl Peak Lab is a Charlottesville VA-based company focused on developing screening solutions to detect colorectal cancer.
– The company raised $1.5M in seed funding.
– The round was led by undisclosed investors.
– The new investment will be used to further develop novel imaging technology to detect anomalies of the gastrointestinal tract at the earliest stage and to invest in its Artificial Intelligence platform to aid in early detection.